Showing posts with label casein. Show all posts
Showing posts with label casein. Show all posts

Wednesday, 30 January 2019

Milk opioid peptides and dipeptidyl peptidase-4 (DPPIV) linked to autism

So: "we have concluded that milk-derived opioid peptides and DPPIV [dipeptidyl peptidase-4 (DPPIV)are potentially factors in determining the pathogenesis of autism."

That was the quite sweeping statement made in the paper published by Beata Jarmołowska and colleagues [1]. It continues a quite a long running research topic in autism circles (see here and see here) on whether the chemical arrangement of certain dietary components *might* have an important biological effect on at least some people diagnosed as being on the autism spectrum.

The Jarmołowska paper is open-access so there is no real need for me to go over the suggested hows-and-whys of some diets being potentially related to (some) autism. If you need some further reading on the topic, I'll direct you to other posts on this blog where I've discussed this 'gluten and casein' issue (see here) and onward, my professional interest in it for quite a few years.

The aim of the Jarmołowska study was to determine "BCM7 [β-casomorphin-7influence on DPPIV functioning in children with ASD in comparison to healthy children." 'Healthy children' is the term for the control group used by the authors by the way, not me. They "examined content and activity of serum DPPIV, content of BCM7 in serum and urine, and studied the effect of hydrolysed bovine milk, as a source of opioid peptides, on DPPIV gene expression in peripheral blood mononuclear cells (PBMC) in both groups."

Results: "We found that the content of BCM7 in serum was significantly higher (p < 0.0001) in ASD than in the control group." Urine concentrations of BCM7 were not significantly different among those with autism compared with controls. Also: "Concentration of DPPIV was found to also be significantly higher in serum from ASD children compared to the control group (p < 0.01)."That was about the sum of the differences noted by researchers.

Caveats? Well some. So: "ELISA test enabled identification of BCM7 contents in the serum and urine from patients, as well as in tested peptide extract obtained from hydrolyzed bovine milk." Authors do mention how the testing was carried out "in triplicate" following a previously published protocol. I don't dispute the results they got but am not exactly enamoured with the ELISA method used. I'd much rather see the analysis undertaken using something like mass spectrometry or similar technology, given the precision that comes with such methods (see here) based for example, on the use of internal standards. Perhaps if the authors still have their samples, they might consider further analyses if available to them?

Although researchers provide quite a bit of information about their participant groups, I also noted one important detail to be missing: were any of their participants - diagnosed with autism or not - following any special dietary regime? Y'know, they talk about casein (milk) free diets and how such diets are supported by "numerous scientific reports." So I guess in a cohort of 86 children diagnosed with autism, at least a few of them might be following such a dietary intervention? I've searched their paper but couldn't find anything to say that they were or weren't.

Putting such issues to one side, I don't want to take anything away from the Jarmołowska findings. As they end their paper: "this issue requires further investigation." I wouldn't disagree.

----------

[1] Jarmołowska B. et al. Role of Milk-Derived Opioid Peptides and Proline Dipeptidyl Peptidase-4 in Autism Spectrum Disorders. Nutrients. 2019 Jan 4;11(1). pii: E87.

----------

Monday, 3 September 2018

Exclusion diet plus prebiotics for [some] autism?

"To our knowledge, this is the first study where the effect of exclusion diets and prebiotics has been evaluated in autism, showing potential beneficial effects."

So said the results reported by Roberta Grimaldi and colleagues [1] and the findings of their study attempting to "understand the impact of diet on GM [gut microbiotacomposition and metabolism in ASD [autism spectrum disorder] children and to investigate the modulating potential of B-GOS® intervention on these parameters."

The study by Grimaldi et al was research registered (see here) and included the 'gold-standard' research design: "A randomised, double-blind, placebo-controlled" study. Researchers divided 30 children diagnosed with an ASD into two groups (A and B), which were subsequently further divided into two groups depending on whether they followed an exclusion diet - "mainly gluten and casein free" - or an unrestricted diet based on the analysis of 4-day food diaries. Within those subdivided A and B groups, half received a placebo supplement of maltodextrin whilst the other half received a "prebiotic B-GOS® mixture" over a 6-week period. As well as including 'run-in', 'beginning of treatment' and 'end of treatment' periods, researchers also included a follow-up period of 2 weeks at the end of the study where various behavioural and physiological measures complemented their use during the experimental period.

Results: there were quite a few results reported as a function of baseline variables such as whether or not participants were following an exclusion diet or not, and as a function of the intervention(s). Behaviourally (probably most importantly), researchers reported that: "Results showed consistent reduction over time in anti-sociability score in children on the combination of the exclusion diet and B-GOS intervention, with the most apparent difference occurring at follow-up." This was measured using the autism 'rising' instrument called the A-TEC (see here) and also complemented other results based on the use of the autism spectrum quotient (AQ). As far as I can make out, all other behavioural and psychometric measures used - the "empathy and systemising quotient (EQ-SQ)... and the Spence’s Children Anxiety Scale-Parent version (SCAS-P)" - did not show any significant changes over the study duration.

Gastrointestinal (GI) symptoms were also examined during the Grimaldi study as per the use of "daily questionnaires for GI function and symptoms" and the utilisation of that fabulous graphical resource, the Bristol stool chart. Authors reported no significant changes/differences as a consequence of intervention, although: "Significantly lower scores of abdominal pain (P < 0.05) and bowel movement (P < 0.001) were reported in children following exclusion diets" at baseline. Interesting, in light of other independent results (see here).

Grimaldi and colleagues also provide quite a lot of data following their examination of fecal and urine samples taken over the course of their investigation. This is perhaps not unexpected given their previous research interests in this area and the proud reputation earned at one of the affiliated institutions. The results? Lots of them. Perhaps the most important intervention-wise was the finding of a "significant increase of Lachnospiraceae family" following B-GOS® intervention. The authors talk about this in terms of the production of butyrate (as per their previous research) and the (positive) reputation this stuff is starting to garner.

Other details? Well, going back to the baseline assessment of samples as a function of the use of an exclusion diet or not, there are some interesting findings. So: "Before prebiotic B-GOS® intervention, we evaluated the nutritional impact of exclusion diets (GFCF) and our results showed deficiency in vitamin D intake, which was significant in children on unrestricted diets." This kinda ties into other research which observed that the 'horror' that is a gluten-free, casein-free (GFCF) diet in relation to autism might actually not be that horrible in nutritional terms (see here). I'm also minded to bring in other recent research which suggested that a GF diet might be a bit of a 'fixer' when it comes to vitamin D deficiency issues under certain clinical circumstances [2]. I say this minus any sweeping generalisations or universal application to the label of autism.

Overall the Grimaldi findings are interesting and suggest further investigations are required on the use of prebiotics and diet in autism; perhaps complementing the still-growing interest in the gut microbiota and autism (see here for one example). Mindful also that diet can itself be seemingly affect gut bacterial composition too [3]. As they stand however, the current results aren't yet a glowing endorsement of B-GOS® intervention 'for' autism, mindful of the small participant group eventually included for study and the relatively short-term nature of the Grimaldi trial. We'll see where this goes... although next time, I'd also like to see a more prominent statement about any harms or side-effects encountered or not during the study period. I assume 'not' in the current study but...

----------

[1] Grimaldi R. et al. A prebiotic intervention study in children with autism spectrum disorders (ASDs). Microbiome. 2018 Aug 2;6(1):133.

[2] Zingone F. & Ciacci C. The value and significance of 25(OH) and 1,25(OH) vitamin D serum levels in adult coeliac patients: A review of the literature. Dig Liver Dis. 2018 Aug;50(8):757-760.

[3] Berding K. & Donovan SM. Diet Can Impact Microbiota Composition in Children With Autism Spectrum Disorder. Front Neurosci. 2018 Jul 31;12:515.

----------

Thursday, 31 August 2017

Gluten & casein free diet vs. ketogenic diet for autism: Fight!

OK, use of the word 'fight' in the title of this post looking at the study results published by Omnia El-Rashidy and colleagues [1] is a bit melodramatic but the findings do provide some rather interesting talking points when it comes to the whole 'diet and autism' thing (see here). Not least that this is, I think, the first peer-reviewed research occasion when the use of a gluten and casein-free (GFCF) diet in the context of autism has been pitted under experimental conditions against another dietary intervention of some interest, the ketogenic diet. The GFCF diet by the way, involves the removal of foods containing the proteins gluten, found in bread and other cereal-based products and casein, the primary protein found in milk and other dairy products. The ketogenic diet is not a million miles away from the GFCF diet but focuses more on the use of high fat and low carbohydrate foods (see here). Both diets have at least some experimental evidence to suggest that they may impact on autistic and related symptoms at least for some on the autism spectrum. But the evidence is not exactly strong yet [2] for any universal effect(s)...

The results of the El-Rashidy study: both diets seemed to be associated with improvements on various autism-related measures (including the ATEC) when compared with a "third group" who "received balanced nutrition and served as a control group" for 6 months. But on some measures the ketogenic diet (KD) came out on top: "ketogenic scored better results in cognition and sociability compared to GFCF diet group."

The authors rightly note that more needs to be done in this area before any sweeping generalisations are applied. So: "this study is a single center study with a small number of patients and a great deal of additional wide-scale prospective studies are however needed to confirm these results." Add to that issues such as a lack of double-blinding (a real Achilles heel when it comes to dietary intervention research in the context of autism) and there are several more investigations needed in this area; also potentially including measurement of some biological parameters to further elucidate possible mechanisms of effect (see here for one important suggestion). But don't completely disregard all of the peer-reviewed literature in this area as bunk just yet (see here). And that for some on the autism spectrum, there may truly be a diet-sensitive phenotype to examine [3]...

----------

[1] El-Rashidy O. et al. Ketogenic diet versus gluten free casein free diet in autistic children: a case-control study. Metab Brain Dis. 2017 Aug 14.

[2] Piwowarczyk A. et al. Gluten- and casein-free diet and autism spectrum disorders in children: a systematic review. Eur J Nutr. 2017 Jun 13.

[3] Whiteley P. Nutritional management of (some) autism: a case for gluten- and casein-free diets? Proc Nutr Soc. 2015 Aug;74(3):202-7.

----------

Monday, 10 July 2017

Rare genetic condition manifesting as autism and its management

"We report the case of a young boy with nonverbal autism and intellectual disability, with a rare de novo 1q21.3 microdeletion."

That was the starting point of the article published by Cora Cravero and colleagues [1] (open-access available here). Researchers describe in some detail how a diagnosis of autism spectrum disorder (ASD) was made "on communication and social interaction impairments and restricted, repetitive patterns of behaviour and interests" and what followed: "The patient had early and extreme self-injurious behaviours that led to blindness, complicated by severe developmental regression."

Detailing how "comparative genomic hybridization array identified a de novo 1.4 Mb microdeletion of chromosome 1q21.3" and various associated physiological findings, the Cravero report provides some rather intriguing evidence that the sentence 'science does not know what causes autism' might not necessarily ring true for everyone (see here for other examples). As the authors note: "The 1q21.3 microdeletion seems associated with ID [intellectual disability], dysmorphic features, and early SIB [self-injurious behaviour] and can be a cause of syndromic autism."

One or two particular details are noteworthy in the Cravero findings outside of the idea that the N=1 might be an important concept in relation to the autism spectrum.

First, is the quite extreme effects that self-injurious behaviour (SIB) in the context of autism can have on a person. This child was blinded by their extreme SIB: "intense and repeated mutilations of cheekbones and eyes, culminating in a bilateral blindness at the age of 4 years by intumescent white cataract after numerous surgical complications." As I've mentioned before on this blog, SIB can in some cases lead to some very complicated adverse health outcomes (see here) that are not uncommon to the autism spectrum (see here). There is however a brighter note to add to the SIB experienced by this child as the authors noted that a range of interventions seemed to help alleviate some of the challenging behaviours linked to such actions. I note for example that naltrexone - the opiate antagonist - was utilised to "decrease the endorphin sensation seeking procured by SIB and diminish SIB." This follows something of a resurgence in interest in this medicine (see here) and is music to my own research ears (see here).

Second, is a little detail mentioned about the eating habits of this child: "a diet almost exclusively made up of dairy products." Alongside some accompanying details on how "intestinal transit was altered, with episodes of diarrhoea (false constipation), encopresis, and coprophagia" and I'll just say that this is something I've heard quite a bit down my years of autism research. Alongside the use of lactulose to aid the bowel issues and the anti-opioid effect of naltrexone (yes, the protein in dairy products does break down into opioid-like compounds), I'm wondering whether some of the research I've been involved with down the years looking at casein-free diets might also be relevant too (see here)?

Finally, I need to draw your attention to the increasingly popular idea that regression is a part of quite a few cases of autism (see here). Indeed the pattern of autism + ID particularly being over-represented when it comes to regression in the context of autism (see here) seems to be borne out by the case report detailed by Cravero et al.

It is good to hear that after "a year of hospitalization" the outcomes reported on this child were quite a bit more favourable than where he began. So: "His mood was stable, without tantrums or irritability, and he felt pleasure without crippling stereotypes. The SIB were limited to small low intensity fists against his helmet or his cheekbone, occurring from time to time." Further: "During the best of times he wandered half-days without helmet, smiling and exploring his environment using tactile gestures."

----------

[1] Cravero C. et al. Management of Severe Developmental Regression in an Autistic Child with a 1q21.3 Microdeletion and Self-Injurious Blindness. Case Rep Psychiatry. 2017;2017:7582780.

----------

Thursday, 14 April 2016

#Breadgate and nutritional psychiatry

The review paper by Paola Bressan & Peter Kramer [1] (open-access) titled: 'Bread and Other Edible Agents of Mental Disease' has been getting a few people a little hot under the collar recently. With it's own Twitter hashtag #breadgate it looks like the idea that certain foods might have something of a bearing on "human behaviour and mental health" has not been received particularly well. I might add that this not the first time that such ideas have been entertained (see here) but there was no such outcry on previous occasions...

As anyone who drops by this blog might know, I'm quite interested in the idea that what we eat and how it's metabolised might have some important implications for SOME people in terms of not just their physical health but also other facets covering behaviour and cognition. I've also talked about it in the peer-reviewed domain quite a bit too using conditions such as phenylketonuria (PKU) as a template. In their latest paper, Bressan & Kramer discuss the quite long-running idea that [some] cereal grains, the starting material for foods like bread, might have some interesting physiological effects that could have a bearing on mental health and wellbeing.

I should at this point mention that I was invited to peer-review the Bressan / Kramer article. I accepted (given my research in this area) and as well as providing a review also let the editor and authors know that my view whilst as unbiased as possible did come alongside a few conflicts of interest (COIs) such as the book that graces the edge of this blog. The journal editor accepted this fact and my comments alongside those of a far more notable researcher were included in the peer-review process.

The Bressan / Kramer paper presents quite a thorough overview of the research looking at food and psychiatry. The language is quite stark in places as words like 'defect' and 'derangement' are included in the text (something that I queried during peer-review) and with a sub-heading titled 'Diet as a Cure' the authors are pretty forth-right in their interpretation of the available peer-reviewed evidence. I would be perhaps less strong in any claims made but ho-hum. I might add that this is not the first time that this authorship team have talked about big hypotheses...

Without seeming like I am springing to the defence of the Bressan / Kramer paper I have decided to list a few previous blog entries that I've written about other relevant texts in the peer-reviewed domain that add something to the discussions in this area. I'm sure that Bressan / Kramer if they have heard about the 'discussions' around their paper are able to defend their writings and so I'm not doing this to somehow cover their backs. I do however think it is important to talk about this topic and this is as good an opportunity as any...

So:

Brain and gut in autism: a historical perspective
For many years now, diet and [some] autism has been discussed. The work of the late Curt Dohan was the leader in this emerging field and his suggestion that [some] schizophrenia might have a dietary component. Before you ask it, no, no-one has ever said that diets devoid of gluten and casein are some sort of cure-all for all autism... they're not. But that does not mean there might be 'best responders' to this type of intervention (see here) in terms of their effect on some behaviours linked to autism. The mechanism for any effect from diet could also be multi-fold (see here).

Psychotic symptoms managed by a gluten-free diet?
Yes. it's a case report, but there are quite a few of them in the peer-reviewed literature talking about dietary manipulations seemingly affecting often quite severe psychiatric presentation. There are more controlled trials too if you want to have a look...

More gluten sensitivity and schizophrenia
The immune system seems to be in the ascendancy when it comes to psychiatry these days (see here also) and diet has been mentioned as an influencing variable on immune function...

Gluten free diet adherence reduces depression in coeliac disease
Building on the idea that coeliac disease - that archetypal autoimmune condition where gluten is the baddie - might have quite a few more 'presentations' than just the physical, there is some emerging peer-reviewed evidence to suggest that adherence to a gluten-free diet might have multiple benefits for certain groups.

Just what is 'non-coeliac gluten sensitivity'?
The idea that outside of coeliac disease there may be a spectrum of 'gluten-related ills' is not a new one. There are still gaps in the research literature and in particular, whether non-coeliac gluten sensitivity (NCGS) might intersect with certain behavioural and/or psychiatric labels but...

Schizophrenia and milk
With the focus also on milk, or rather the casein protein that is also said to produce peptide metabolites that might not be a millions miles away from various opioid-like compounds like to gluten digestion (hence the name casomorphins), I've included reference to the David Niebuhr et al paper too titled: 'Association between bovine casein antibody and and new onset schizophrenia among US military personnel'. Correlation is not causation but this and other data are interesting.

Intestinal permeability: an emerging scientific area (also with autism in mind)
Gluten 'punching holes in the gut' is mentioned in some of the discussion about the Bressan / Kramer paper and with it the words 'leaky gut' make an appearance. As per my ramblings on some of the peer-reviewed science in this area, there is emerging evidence for this concept in relation to specific conditions including the fantastic paper by Laura de Magistris and colleagues [3] citing food as having a potentially modifying effect.

These are just a selection of the entries that I've written on this blog covering the topic of nutritional psychiatry (see here) but there are more. Accepting that "mental disease" (authors term not mine) covers quite a lot of ground and even within the various labels we have a lot of heterogeneity (see here for example) I would suggest that more research is required into how diet might influence behaviour and psychiatry. The paper by Dash et al [3] similarly titled: 'Diet and common mental disorders; the imperative to translate evidence into action' recently published (in the same family of journals) reiterates that there is more to do in this area including the identification of potential 'best responders' to this type of approach. Diet again, is not put forward as a cure-all for every single label/condition, but that doesn't mean it might not be useful to look at it for some.

I know there is still quite a lot of hostility to the idea that what we eat (or don't eat) might have a bearing on something other than physical health. I'm not advocating for any universal 'change your diet to this' approach to manage mental health issues but I do believe that there is enough peer-reviewed science out there to merit some further sensible discussions on the topic...

Music to close, and what else but Toast... a little bit of toast.

----------

[1] Bressan P. & Kramer P. Bread and Other Edible Agents of Mental Disease. Front Hum Neurosci. 2016 Mar 29;10:130.

[2] de Magistris L. et al. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr. 2010 Oct;51(4):418-24.

[3] Dash SR. et al. Diet and common mental disorders; the imperative to translate evidence into action. Front. Public Health | doi: 10.3389/fpubh.2016.00081.

----------

ResearchBlogging.org Bressan P, & Kramer P (2016). Bread and Other Edible Agents of Mental Disease. Frontiers in human neuroscience, 10 PMID: 27065833

Wednesday, 23 December 2015

Prevalence of schizophrenia in China up: was Dohan (partially) right?

"The prevalence of schizophrenia in China has more than doubled between 1990 and 2010, with rates being particularly high in the most developed areas of modern China."

So said the study results from Chan and colleagues [1] reviewing the collected peer-reviewed "epidemiological studies of schizophrenia in mainland China published between 1990 and 2010."

Taking into account data from 42 eligible trials covering some "2 284 957 persons, with 10 506 diagnosed with schizophrenia" researchers applied some statistical wizardry "to estimate the probability of case of schizophrenia ("prevalence") by type of residency in different years."

The figures make for interesting read as the estimated lifetime prevalence rate of schizophrenia steadily rose between 1990, 2000 and 2010. Further: "In 1990 there were 3.09 (2.87-3.32) million people in China affected with schizophrenia during their lifetime. The number of cases rose to 7.16 (6.57-7.75) million in 2010, a 132% increase, while the total population increased by 18%." As per my opening sentence, area of residence in terms of industrialisation and urbanisation also seemed to exert something of an effect. I might add that this data also seems to have appeared in another publication [2] (open-access).

I have no doubt that the reasons behind the increase in cases of schizophrenia in China are likely to be numerous and complex. To say that there may be just one factor universally contributing to every case of schizophrenia in China would be a fool-hardy thing to state in these days of plural labels (including 'the schizophrenias') and multi-factorial explanations of how someone arrives at such a diagnosis. That screening and assessment facilities have no doubt changed over the course of 20 years in China is also worth mentioning.

I do however want to forward one idea that perhaps requires a little bit more investigation as potentially being pertinent to the increase in prevalence rates: food, and specifically, the idea that gluten consumption may have played a role as per the ideas of the late Curt Dohan. Quite a good overview of 'Dohan's hypothesis' can be read here by Dr Emily Deans from the Evolutionary Psychiatry blog. He basically suggested that where grain (and milk) consumption were rare, so schizophrenia tended to be rare. Conversely, where populations started to take on board grain (and milk) as a staple food, so admission rates for schizophrenia increased. Dohan produced quite a few papers discussing this hypothesis including this one [3] including the idea that foods containing gluten and casein can produce exorphins akin to certain opiates.

I've always been interested in this work given my research affinity to the idea that certain foods might have some important 'effects' on certain behaviours or diagnostic labels covering certain behaviours [4]. That ideas about gluten and casein potentially being important to 'some' autism [5] have generally emerged from the discussions in schizophrenia perhaps highlights how central Dohan has been given also the tangled history that schizophrenia and autism have at times shared.

In recent times, there has been more interest in Dohan's hypothesis and the idea that some people diagnosed with schizophrenia (or on the schizophrenia spectrum) may demonstrate specific genetic and biological issues associated with gluten and casein. I've blogged about it a few times including the idea of immunological gluten 'sensitivity' in schizophrenia (see here and see here), a possible role for food and gastrointestinal (GI) inflammation in cases (see here) allied to a possible role for milk antibodies in relation to potentially predicting the development of schizophrenia (see here). All of this set in the context of some growing interest in food and nutrition within psychiatry (see here). Such research has met with some criticism down the years but more and more the peer-reviewed evidence is highlighting how things like immune function and the concept of inflammation do seem to be important to various psychiatric labels.

Some of the elements discussed by Dohan and others seem to make sense in the context of schizophrenia and China. The idea of "rates being particularly high in the most developed areas of modern China" might imply that food and the types of food eaten in more developed areas may be slightly different from those in less developed (more traditional) areas of the country. In the context of milk consumption and given the important biology associated with milk consumption in China (quite a high proportion of the population are deemed lactose intolerant), one might also envisage some connection.

I'm not saying that a complex condition like schizophrenia is all down to food within the data coming out of China. What I am saying is that one might entertain the idea that as part of suite of potentially important variables, what someone is eating may have some bearing on their psychiatric health and wellbeing and hence potentially be amenable to change...

Music: Descendents - Everything Sucks. Dedicated to Kylo Ren and, as one of my brood observed when watching the latest Star Wars film, the fact that he is rather an angry man throughout. I'd like to think in subsequent films we might see a 'lighter' side to ole' Ben...

----------

[1] Chan KY. et al. Prevalence of schizophrenia in China between 1990 and 2010. J Glob Health. 2015 Jun;5(1):010410.

[2] Chan KY. et al. Urbanization and the prevalence of schizophrenia in China between 1990 and 2010. World Psychiatry. 2015;14(2):251-252.

[3] Dohan FC. Genetic hypothesis of idiopathic schizophrenia: its exorphin connection. Schizophr Bull. 1988;14(4):489-94.

[4] Whiteley P. et al. Gluten- and casein-free dietary intervention for autism spectrum conditions. Front Hum Neurosci. 2013 Jan 4;6:344.

[5] Whiteley P. Nutritional management of (some) autism: a case for gluten- and casein-free diets?  Proc Nutr Soc. 2015 Aug;74(3):202-7.

----------

ResearchBlogging.org Chan KY, Zhao FF, Meng S, Demaio AR, Reed C, Theodoratou E, Campbell H, Wang W, Rudan I, & Global Health Epidemiology Reference Group (GHERG) (2015). Prevalence of schizophrenia in China between 1990 and 2010. Journal of global health, 5 (1) PMID: 26649171

Thursday, 29 October 2015

Is a GFCF diet for autism inherently unhealthy? (part 2)

Consider today's entry as a sort of continuation of a previous post looking at the 'horror' that is a gluten-free, casein-free (GFCF) diet for autism (see here).

This time around I'm bringing the paper by Salvador Marí-Bauset and colleagues [1] to your attention and the idea that things might not necessarily be all bad when it comes to the use of a GFCF diet in terms of nutritional quality nor anthropometric values. Indeed, subject to the correct dietetic input, that there may be some important food exchanges going on when a diet devoid of gluten and casein is instigated specifically where an autism diagnosis is mentioned.

I realise that not everyone is as enthusiastic about how food might impact on behaviour and development with at least some autism in mind as I am, but science is coming around to the idea that what we eat (or not) might have some important influences on our being (see here). Appreciating that the GFCF diet is also probably not for everyone [2] (see here also), there continues to be some 'appetite' for such an approach for at least some autism [3]. It is therefore important to understand a little more about what might be the positives and negatives to following such a restrictive dietary regime.

Marí-Bauset et al report results for some 20 children with autism following a GFCF diet compared with 85 "on a regular diet in Valencia (Spain)." This follows a scheme of work from this authorship group looking at various aspects of nutrition when applied to autism [4]. Upon analysing 3-day food diaries, researchers concluded that: "Those on the GFCF diet had a lower weight, body mass index, and total energy, pantothenic acid, calcium, phosphorus and sodium intake." Further however, the GFCF group had: "a higher intake of fiber, legumes, and vegetables" and something of a more favourable fat intake profile that non-GFCF dieters. That last point also ties into other work from the authors [5].

As per the part 1 entry on the nutritional and health related aspects to a GFCF diet for autism (here it is again) there are some details in the Marí-Bauset data that perhaps require some clinical input. I'm thinking specifically about the lower calcium intake in this case, bearing in mind calcium and autism is a very complicated issue (see here) and some continued questioning about the more general link between calcium intake and bone health. The idea that those following a GFCF diet might also present with a lower weight and body mass index (BMI) is also interesting; particularly in light of quite a lot of the chatter in this area focusing on elevated weight and the health effects that can have with autism in mind (see here). I might add that I am in no way endorsing a GFCF diet (or any other diet) for weight loss or management; that's not my job.

The slightly more positive idea that those following a GFCF diet might have a better intake of vegetables and legumes probably also tied into a higher intake of fibre is important. I've previously talked about where the extremes of a limited diet can lead when it comes to [some] autism (see here). Although supplementation has its place in terms of as and when specific deficiencies are present and identified (see here) I think most people would agree that consumption of foodstuffs like fruit and vegetables probably do a better job of supplying nutritional needs than a pill (most of the time). In that respect, one might assume that those on a GFCF diet with more favourable vegetable consumption profile, might be slightly less prone to certain deficiencies. As per other research in this area, we would need a little more biological testing to be sure (see here). The specific idea that fibre intake was higher for the GFCF group is also an important point if one considers fibre to be an essential component when it comes to gastrointestinal (GI) motility, again, as has been specifically mentioned with autism in mind (see here).

In short, and with more research required, the horror that is a GFCF diet for autism might actually with the right clinical input, not be so horrible...

Music: Lily Allen - The Fear.

----------

[1] Marí-Bauset S. et al. Nutritional Impact of a Gluten-Free Casein-Free Diet in Children with Autism Spectrum Disorder. J Autism Dev Disord. 2015 Oct 1.

[2] Buie T. The relationship of autism and gluten. Clin Ther. 2013 May;35(5):578-83.

[3] Whiteley P. Nutritional management of (some) autism: a case for gluten- and casein-free diets? Proc Nutr Soc. 2015 Aug;74(3):202-7.

[4] Marí-Bauset S. et al. Nutritional status of children with autism spectrum disorders (ASDs): a case-control study. J Autism Dev Disord. 2015 Jan;45(1):203-12.

[5] Marí-Bauset S. et al. Fat intake in children with autism spectrum disorder in the Mediterranean region (Valencia, Spain). Nutr Neurosci. 2015 May 28.

----------

ResearchBlogging.org Marí-Bauset S, Llopis-González A, Zazpe I, Marí-Sanchis A, & Suárez-Varela MM (2015). Nutritional Impact of a Gluten-Free Casein-Free Diet in Children with Autism Spectrum Disorder. Journal of autism and developmental disorders PMID: 26428353

Monday, 7 September 2015

Gluten- and casein-free diets and autism: the Hyman results (at last)

"Although these findings must be interpreted with caution because of the small sample size, the study does not provide evidence to support general use of the GFCF [gluten-free/casein-freediet."

So said the results of the study finally published by Susan Hyman and colleagues [1] detailing the effects (or not) of a small (n=14) "double-blind, placebo-controlled challenge study" of the use of a diet devoid of gluten and casein for young children diagnosed with an autism spectrum disorder (ASD). If you really want some background history to this often controversial area of autism research, look no further than some of my past musings on this blog (see here and see here) or if you wish, in peer-reviewed form [2].

I say 'finally' in that previous sentence about publication because there has been a considerable degree of waiting for these results to appear in complete peer-reviewed form given that the trial was initially registered in 2004 and things were all supposed to have been wrapped up in 2009 (see here for the ClinicalTrials.gov entry). Some people with their eyes and ears to the autism research grapevine will have probably heard about some of the whys and wherefores of the delay in publishing these results, but I'm not going to get too involved in that here.

Unfortunately the paper is not open-access at the present time but I'll give you a summary of some of the mechanics and findings:

  • Some 66 children were initially assessed for eligibility. This was whittled down to 22 kids taking into account those who declined to participate and those who "did not meet inclusion criteria." That inclusion criteria by the way "required children to be enrolled in a comprehensive applied behavior analysis (ABA) intervention program from one of two community agencies" as well as excluding those where seizures were part of clinical presentation and/or the "presence of a chronic illness in addition to ASD that required medical management, celiac disease, documented food allergy to wheat or milk, nutritional compromise such as iron deficiency that required treatment, and family inability to complete rating scales and assessments in English."
  • The study design was interesting. It included an implementation phase whereby a GFCF was put in place over the course of 2 weeks (baseline) and maintained for at least 4 weeks. Then came the challenge phase which consisted of weekly challenges to the diet for 12 weeks including one of the following: "foods that contained gluten only, casein only, both gluten and casein, or neither (placebo)." Finally, there was a maintenance period where families were free to "maintain, modify, or abandon the GFCF diet in this phase."
  • Various assessments were carried out throughout the study phases covering areas of "physiologic functioning, challenging behaviors (not specific to ASD), and behaviors associated with ASD."
  • Results: well, data for 14 of the 22 children were analysed as a function of attrition and or other factors such as "laboratory exclusion criteria." First and foremost we are told: "No serious adverse events were reported during the trial." First, do no harm and all that. When looking at sleep quality and quantity, stool frequency and type, a measure of ADHD (attention-deficit hyperactivity disorder) and a measure of behaviours associated with autism (the Ritvo-Freeman Real Life Rating Scales), authors reported no significant effect following dietary challenges. In other words: "experimental challenges [to the GFCF diet] were not reliably associated with more frequent ASD behaviors." That being said: "All of the families elected to continue the diet for the 12 weeks after completion of the challenges."
  • There are some significant strengths to this data based on close monitoring of adherence to the diet, controlling the consumption of gluten and casein levels in challenge snacks and the use of ABA in terms of "stable, consistent educational and behavioral services."
  • Likewise however, there are some notable issues associated with the study and the findings outside of the small participant group, not least the emphasis on 'dietary challenge' and importantly the fact that researchers "excluded children who had known gastrointestinal disorders, who might have been more likely to respond positively to dietary restriction." This last point ties in well with other literature in this area [3]. I might add that "individualized supplementation was added for a few participants when deemed necessary by the study dietitian to address low intake of iron, calcium, or vitamin D." Interesting (see here).
  • The authors conclude that their study "does not provide evidence to support general use of the GFCF diet" with caveats. 

I can imagine that the Hyman results are probably going to generate some interesting discussions depending on your view of a GFCF diet for autism. I have a professional interest in this topic given some of my research history in this small part of the autism research arena [4] but have tried to stay as objective as possible as per other entries on this topic (see here).

Despite any potential bias I might have, I do still think there is more to see in this area of diet and autism. I've talked before about the idea that the diagnosis of autism is by no means protective against other conditions/labels appearing including those related to issues with gluten for example (see here). This similarly applied to milk also (see here). Some of other peer-reviewed research that I've also been a part of has hinted that there may be 'best responders' to this type of intervention [5] (see here for more discussion); something which ties in well with the concept of plurality and autism (see here).

That caveat about the Hyman study excluding children with known gastrointestinal (GI) disease is also worth re-iterating. Again, this takes autism research into some controversial areas (see here) but as per recent data, both functional (see here) and pathological bowel disorders (see here) do seem to over-represented in cases of autism, so one might see this as an area ripe for further dietary investigations. Indeed, one assumes we might see if there is anything in such an association as and when the Harland Winter trial sees the peer-reviewed light of day (hopefully quite soon).

----------

[1] Hyman SL. et al. The Gluten-Free/Casein-Free Diet: A Double-Blind Challenge Trial in Children with Autism. Journal of Autism and Developmental Disorders. 2015. Sept 5.

[2] Whiteley P. et al. Gluten- and casein-free dietary intervention for autism spectrum conditions. Front Hum Neurosci. 2013 Jan 4;6:344.

[3] Genuis SJ. & Bouchard TP. Celiac disease presenting as autism. J Child Neurol. 2010 Jan;25(1):114-9.

[4] Whiteley P. et al. The ScanBrit randomised, controlled, single-blind study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders. Nutr Neurosci. 2010 Apr;13(2):87-100.

[5] Pedersen L. et al. Data mining the ScanBrit study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders: behavioural and psychometric measures of dietary response. Nutr Neurosci. 2014 Sep;17(5):207-13.

----------

ResearchBlogging.org Hyman, S., Stewart, P., Foley, J., Cain, U., Peck, R., Morris, D., Wang, H., & Smith, T. (2015). The Gluten-Free/Casein-Free Diet: A Double-Blind Challenge Trial in Children with Autism Journal of Autism and Developmental Disorders DOI: 10.1007/s10803-015-2564-9

Friday, 5 June 2015

Dietary supplementation and autism (and the horror of a GFCF diet)

As perhaps expected, the results reported by Patricia Stewart and colleagues [1] suggesting that: "Few children with ASD [autism spectrum disorder] need most of the micronutrients they are commonly given as supplements, which often leads to excess intake" has generated some interesting media headlines given their mention of the words "gluten/casein-free diet (GFCF)".

A case in point is an article titled: 'Autism Diets' Do Not Provide Children With Adequate Supplementation, Can Lead To Overuse which aside from making little sense (do not provide children with adequate supplementation?) seems to be using the Stewart paper to take pot shots at the mention that GFCF diets have some research (yes, peer-reviewed research) history with autism in mind. Bearing in mind that I have something of an interest in this area, I'm gonna go through some of the findings reported by Stewart et al with a slightly different mindset albeit based on the science to hand.

Drawing on participants with autism (N=288) recruited via the Autism Speaks Autism Treatment Network (ATN) researchers set about examining "dietary supplement use and micronutrient intake in children with ASD." This was accomplished by analysing data from 3-day diet/supplement records "relative to GFCF diet status."

There were a few important results to mention following analysis of [trained] caregiver food/supplement diaries for children based on the reported data and other write-up of the findings:

  • Overall, children with ASD were consuming similar amounts of micronutrients as children without ASD. "They also had the same deficits in vitamins D, E, calcium, potassium, and choline as the general pediatric population." I'll come back to some of the details of this shortly.
  • Children receiving GFCF diets (~20%) had similar micronutrient intake to those not following a GFCF diet. Indeed: "Children on the GFCF diet consumed more magnesium and vitamin E" and "Children on this diet were more adequately supplemented with vitamin D." These findings hark back to other research suggestions that the 'horror' that is a GFCF diet might not be as poor in nutrition as some people might imagine (see here). I might add that if readers look elsewhere on this blog, you might notice that yours truly has written a book about how a GFCF diet can be implemented safely and nutritiously without the requirement for high levels of supplementation when it comes to autism (sorry for the blatant self-publicity).
  • "Dietary supplements, especially multivitamin/minerals, were used by 56% of children with ASD." Using a GFCF diet seemed to be associated with greater supplement use (78% vs 56%) compared with those not following such a diet. I assume this is because of the perception that a GFCF diet is 'nutritionally inadequate' when it comes to important minerals such as calcium for example. That being said: "Calcium supplementation was equally inadequate in those on and off the diet." This is interesting and perhaps relevant to other work on diet, calcium, bone health and autism (see here).
  • "Despite different eating behaviors, children with ASD received much of their needed micronutrients from food consumption." The authors suggest that this might have something to do with the various food fortification strategies in place these days, but likewise "may also be responsible for the overconsumption of certain nutrients by children with ASD."
  • "Even when supplements are used, careful attention should be given to adequacy of vitamin D and calcium intake." Coming back to the idea that deficiencies noted in this sample of children with autism are not so dissimilar from that seen in the general population, the suggestion that issues such as vitamin D deficiency or insufficiency might be over-represented when it comes to autism continues an emerging research theme (see here).

There are some important points to take from the Stewart paper bearing in mind that 3-day food / supplement diaries are really only providing a snapshot of food / supplement intake and say nothing about the biological levels of various nutrients when it comes to autism. As per the numerous entries on this blog about where eating habits can go wrong with autism in mind (see here) and what happens when vitamin/mineral supplementation in autism is put to the double-blind test (see here) I'd be slightly guarded about drawing too many sweeping conclusions from the new data.

"In clinical practice, each patient needs to be individually assessed for potential nutritional deficiencies or excess." So says Dr Stewart in the press release accompanying the study. I'd be minded to agree with that sentiment given the idea of plurality in autism (see here) and the potential for various biochemistry that can follow a diagnosis (see here and see here) potentially impacting on food and feeding habits. As I've said many times before, receipt of the label of 'autism' or 'autism spectrum disorder' should be a starting point for quite a bit more clinical inspection and not the finishing line...

----------

[1] Stewart PA. et al. Dietary Supplementation in Children with Autism Spectrum Disorders: Common, Insufficient, and Excessive. Journal of the Academy of Nutrition and Dietetics. 2015. June 4.

----------

ResearchBlogging.org Patricia A. Stewart, Susan L. Hyman, Brianne L. Schmidt, Eric A. Macklin, Ann Reynolds, Cynthia R. Johnson, S. Jill James, & Patricia Manning-Courtney (2015). Dietary Supplementation in Children with Autism Spectrum Disorders: Common, Insufficient, and Excessive Journal of the Academy of Nutrition and Dietetics

Saturday, 4 October 2014

The gut-brain axis and schizophrenia

A micropost to direct your attention to the recent paper by Katlyn Nemani and colleagues [1] titled: 'Schizophrenia and the gut-brain axis'. Mentioning words like that, I couldn't resist offering a little exposure to this review and opinion piece, drawing on what seems to be some renewed research interest in work started by pioneers such as the late Curt Dohan [2].

The usual triad of gastrointestinal (GI) variables - gut barrier, gut bacteria and gut immune function - are mentioned in the article, concluding that: "A significant subgroup of patients may benefit from the initiation of a gluten and casein-free diet" among other things. Not a million miles away from related suggestions when it comes to something like the autism spectrum disorders (ASDs) (see here) bearing in mind the concept of overlapping spectrums (see here) and the [plural] schizophrenias.

I'm also minded to hat-tip another research team including Emily Severance and colleagues who are going great guns when it comes to the whole GI-food link in cases of schizophrenia and beyond (see here for my recent discussion of some of her work). Another of her quite recent papers [3] on cerebrospinal fluid (CSF) levels of antibody response to wheat gluten and bovine milk in first-episode schizophrenia represents another master-class of research in this area. Their suggestion of potential evidence for a leaky blood-CSF barrier is something else which might stimulate further research in this area including some mention for the molecular handyperson that is melatonin among other things to "protect against blood-brain barrier and choroid plexus pathologies". Such findings might also be relevant for other CSF issues reported with schizophrenia in mind (see here).

And whilst we're talking all-things biological membrane permeability and schizophrenia, I'll also link to the paper by Julio-Pieper and colleagues [4] (open-access) reviewing some of the evidence on the 'controversial association' between intestinal barrier dysfunction and various conditions (also covering some of the literature with autism in mind too). Mainstream here we come?

----------

[1] Nemani K. et al. Schizophrenia and the gut-brain axis. Prog Neuropsychopharmacol Biol Psychiatry. 2014 Sep 17. pii: S0278-5846(14)00168-7

[2] Dohan FC. Cereals and schizophrenia data and hypothesis. Acta Psychiatrica Scandinavica. 1966; 42: 125–152.

[3] Severance EG. et al. IgG dynamics of dietary antigens point to cerebrospinal fluid barrier or flow dysfunction in first-episode schizophrenia. Brain Behav Immun. 2014 Sep 17. pii: S0889-1591(14)00462-0.

[4] Julio-Pieper M. et al. Review article: intestinal barrier dysfunction and central nervous system disorders - a controversial association. Aliment Pharmacol Ther. 2014 Sep 28.

----------

ResearchBlogging.org Nemani, K., Ghomi, R., McCormick, B., & Fan, X. (2014). Schizophrenia and the gut–brain axis Progress in Neuro-Psychopharmacology and Biological Psychiatry DOI: 10.1016/j.pnpbp.2014.08.018

Wednesday, 6 August 2014

Gastrointestinal response to A1 vs A2 milk

I want to talk about the findings from Ho and colleagues [1] today, and in particular their observation of: "differences in gastrointestinal responses in some adult humans consuming milk containing beta-casein of either the A1 or the A2 beta-casein type". If you're wondering why such a paper finds it's way on to a blog predominantly about autism research, well stay with me on this rather long blogging entry...

Start your engines... @ Wikipedia 
Before progressing, I am going to put a sort of COI (conflict of interest) statement into this blog post. As part of my day job, I have, down the years, been party to some conversations on A2 milk and how one might scientifically test some of the claims / assumptions made about this milk with specific populations in mind. That also our lab has been looking at analytical ways of differentiating A1 and A2 milk from each other is another COI, allowing for the fact that I am neither a consumer of, nor advocate for, anything to do with any of the white stuff.

In case you're not up to speed with A1 and A2 milk, well, it all boils down to type of cow and type of milk produced. Anyone with a handle on autism research history will have probably heard about the opioid-excess hypothesis [2]. The long-and-short-of-it is that casein, the protein found in milk and dairy products, is eventually metabolised into it's constituent amino acids. Along the way, short chains of amino acids called peptides are formed. Some of these peptides look (chemically) similar to compounds like morphine and are hence referred to as the casomorphins (casein derived morphine-like). The opioid-excess hypothesis suggested that these exogenously derived peptides mimic some of our own naturally occurring morphine-like compounds that we all have, and disrupt typical functioning in this area to such an extent that it may correlate with some of the signs and symptoms called autism. I talked about something similar quite recently.

Granted, such a model looks a little simplistic these days knowing what we think we know about the very plural autisms and the ESSENCE of cormorbidity. Still, such a hypothesis did seem to fit in well with the suggested effectiveness of a casein-free (and gluten-free) diet for some on the autism spectrum, and also some work looking at the opioid receptor blocker that is naltrexone (see here) and autism. It is with the structure of those peptides in mind that we come to the differences suggested for A1 and A2 milk. Y'see not every cow or other mammal produces the same kind of casein protein in their milk and hence peptide formulations can vary also. For A2 casein, the idea is that beta-casomorphin fragment 1-7 (BC 1-7), a peptide formed during digestion is not the same as the BC1-7 from A1 milk (see here) particularly when it comes to a single amino acid change (proline over histidine) [3].

After such a long-winded explanation, we come back to the Ho paper and some interesting findings...

  • First things first, this was a double-blind, randomised cross-over study looking at "gastrointestinal effects" in adults under conditions of either A1 or A2 milk consumption. Two weeks of either A1 or A2 milk consumption (with an appropriate washout period in between) were completed.
  • The very informative Bristol Stool Chart was used to grade poop (stool) consistency alongside other more physiological measures such as faecal calprotectin.
  • Results: "The A1 beta-casein milk led to significantly higher stool consistency values". That and a correlation between stool consistency and reports of abdominal pain for participants when on the A1 milk compared with when on A2 milk. Ergo, it didn't seem that A2 milk did anything over and above A1 milk, rather that consumption didn't seem to be linked to the symptoms noted when drinking A1 milk. 

Appreciating the authors' call for further study in this area, I was intrigued by these results. Not so many moons ago, I came across the paper by Barnett and colleagues [4] talking about greater gastrointestinal (GI) transit time in rats fed A1 milk over A2 milk (see here for some additional commentary from one of the study authors). One might very well overlap those rodent reports with the more recent Ho results in terms of how longer transit time from A1 milk might mean greater discomfort bearing in mind some of the literature on longer transit time and "pain and distension" [5] in certain conditions. Interestingly, the authors ask that research not only focus on confirmation of their results but: "confirmation in a larger study of participants with perceived intolerance to ordinary A1 beta-casein-containing milk" which begs the question: who and what ailments are being reported?

That all being said, not all the literature on A2 milk is so directional. Take for example the paper by Crowley and colleagues [6] (open-access) looking at the question of milk consumption correlating with the functional bowel issue constipation. They concluded that: "that removal of CMP [cow's milk protein] from the diet of children with CFC [chronic functional constipation] significantly increased the number of bowel motions and improved constipation". Their results however did not show any significant effect based on casein type when looking at A1 and A2 milk. Constipation, by the way, is also something talked about with some autism in mind (see here) and particularly the findings from Afzal and colleagues [7] which concluded: "Multivariate regression analysis showed consumption of milk to be the strongest predictor of constipation in the autistic group".

I am quite interested in this whole area of different milks from different animals potentially possessing different qualities which might impact on physiology particularly if eventually applied to conditions like autism, or at least some comorbidity. I think back to the post I did on milk derived opioid peptides and methylation status (see here) as also being important, as might be the work on something like the use of camel milk (see here) bearing in mind the adverse publicity our humped friends have received recently. As per my previous caveat, I don't think we are in a position yet to advocate changes in milk drinking practices for specific groups based on the available literature, but there might be quite a bit more research to do in this important area...

To close, I know this might sound a little odd but am I the only father with young children who know Barry Scott on sight?

----------

[1] Ho S. et al. Comparative effects of A1 versus A2 beta-casein on gastrointestinal measures: a blinded randomised cross-over pilot study. Eur J Clin Nutr. 2014 Jul 2.

[2] Shattock P. & Whiteley P. Biochemical aspects in autism spectrum disorders: updating the opioid-excess theory and presenting new opportunities for biomedical intervention. Expert Opin Ther Targets. 2002 Apr;6(2):175-83.

[3] Truswell AS. The A2 milk case: a critical review. Eur J Clin Nutr. 2005 May;59(5):623-31.

[4] Barnett MP. et al. Dietary A1 β-casein affects gastrointestinal transit time, dipeptidyl peptidase-4 activity, and inflammatory status relative to A2 β-casein in Wistar rats. Int J Food Sci Nutr. 2014 Mar 20.

[5] Cann PA. et al. Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut. May 1983; 24(5): 405–411.

[6] Crowley ET. et al. Does Milk Cause Constipation? A Crossover Dietary Trial. Nutrients 2013; 5: 253-266

[7] Afzal N. et al. Constipation with acquired megarectum in children with autism. Pediatrics. 2003 Oct;112(4):939-42.

----------

ResearchBlogging.org Ho, S., Woodford, K., Kukuljan, S., & Pal, S. (2014). Comparative effects of A1 versus A2 beta-casein on gastrointestinal measures: a blinded randomised cross-over pilot study European Journal of Clinical Nutrition DOI: 10.1038/ejcn.2014.127

Thursday, 31 July 2014

Dipeptidyl peptidase (DPP) IV and autism: supporting opioid-excess?

Serum levels of dipeptidyl peptidase (DPP) IV were found to be lower in children with autism compared to asymptomatic controls according to the study by Shahid Bashira & Laila AL-Ayadhi [1]. Based on analysis by ELISA, researchers concluded that "alterations in the plasma level of DPP IV play a role in the pathophysiology of autism".
A sailor went to sea, sea, sea... @ Wikipedia 

Anyone who has followed the autism research scene for any length of time might have already heard about DPP-IV and autism. The paper by Hunter and colleagues [2] (open-access here) and subsequent response [3] highlights some of the discussions in this area relating to the use of the opioid-excess hypothesis [4] as a means to potentially explain some autism. The idea stemming from some earlier work (see here) being that a defect in the functioning of DPP-IV with regards to its ability to degrade proline-rich proteins such as gliadin (gluten) might account for the build-up of gluten derived opioid peptides suggested as part of the opioid-excess theory. Earlier accounts of issues with DPP-IV in relation to the classic gluten-related autoimmune condition coeliac disease (see here for an overview) kinda set the tone [5] for some analysis with autism in mind. Indeed, at least one trial of enzyme-based therapy has also talked about the potential involvement of DPP-IV in some cases of autism [6].

The Bashira paper did not specifically set out to look at the relationship between DPP-IV and dietary elements potentially linked to autism. Instead their focus seemed to be on the involvement of this peptidase in brain physiology and "its possible link to neuroinflammation in autism". DPP-IV has, for example, been discussed with cerebral ischemia in mind as per the results from Röhnert and colleagues [7] although I hasten to add that I am not equating autism and brain ischemia.

I personally feel that quite a bit more research effort is needed in the area of DPP-IV. Lower plasma levels of DPP-IV have been noted in cases of other conditions such as depression [8]. The recent results from Simone Peters and colleagues [9] which talked about "Short-term exposure to gluten specifically induced current feelings of depression" in their cohort (see this post) could fit well with the reduction in gluten peptide degrading abilities potentially present as a consequence of something like lower DPP-IV levels. Indeed, one might also speculate that the suggestion of non-coeliac gluten sensitivity (NCGS) may actually reflect involvement of opioid peptides on the basis of such a correlation...

I'm also taken back to some work by Vojdani and colleagues [10] which talked about anti-CD26 autoantibodies being present in a "significant percentage of children with autism". CD26, a surface glycoprotein used synonymously with DPP-IV, was suggested to show involvement as a function of "dietary peptides, bacterial toxins and xenobiotics bind[ing] to lymphocyte receptors and/or tissue enzymes, resulting in autoimmune reaction in children with autism". Their follow-up study [11] further added to the literature in this area and how "Dysfunctional membrane peptidases and autoantibody production may result in neuroimmune dysregulation and autoimmunity" in relation to autism. Autoimmunity and autism y'say?

As per the cycles of scientific research, where research areas fall in and out of favour, it does appear that there is a resurgence of interest in elements of the opioid-excess theory with a specific focus on the role of food-derived peptides in relation to at least some autism. The Roy review looking at naltrexone for autism (see here) is one element given the opioid antagonistic effects of this pharmaceutic. The Sokolov paper (with its flaws) looking at beta-casomorphin - the opioid peptide derived from the casein protein - in relation to autism is another. The Trivedi paper (see here) on exogenous opioid peptides and DNA methylation levels adds to the research bundle. Dare I even mention the camel milk and autism connection also being made in the research literature too as a function of different milks and different protein/peptide configurations?

Music to close. Epic by Faith No More.

----------

[1] Bashir S. & AL-Ayadhi L. Alterations in plasma dipeptidyl peptidase IV in autism: A pilot study. Neurology, Psychiatry and Brain Research. 2014; 20: 41-44.

[2] Hunter LC. et al. Opioid peptides and dipeptidyl peptidase in autism. Dev Med Child Neurol. 2003 Feb;45(2):121-8.

[3] Shattock P. et al. Opioid peptides and dipeptidyl peptidase in autism. Dev Med Child Neurol. 2004 May;46(5):357.

[4] Shattock P. & Whiteley P. Biochemical aspects in autism spectrum disorders: updating the opioid-excess theory and presenting new opportunities for biomedical intervention. Expert Opin Ther Targets. 2002 Apr;6(2):175-83.

[5] Smith MW. & Phillips AD. Abnormal expression of dipeptidylpeptidase IV activity in enterocyte brush-border membranes of children suffering from coeliac disease. Exp Physiol. 1990 Jul;75(4):613-6.

[6] Brudnak MA. et al. Enzyme-based therapy for autism spectrum disorders -- is it worth another look? Med Hypotheses. 2002 May;58(5):422-8.

[7] Röhnert P. et al. Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia. J Neuroinflammation. 2012 Feb 28;9:44.

[8] Maes M. et al. Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs. Acta Psychiatr Scand. 1996 Jan;93(1):1-8.

[9] Peters SL. et al. Randomised clinical trial: gluten may cause depression in subjects with non-coeliac gluten sensitivity - an exploratory clinical study. Aliment Pharmacol Ther. 2014 May;39(10):1104-12.

[10] Vojdani A. et al. Infections, toxic chemicals and dietary peptides binding to lymphocyte receptors and tissue enzymes are major instigators of autoimmunity in autism. Int J Immunopathol Pharmacol. 2003 Sep-Dec;16(3):189-99.

[11] Vojdani A. et al. Heat shock protein and gliadin peptide promote development of peptidase antibodies in children with autism and patients with autoimmune disease. Clin Diagn Lab Immunol. 2004 May;11(3):515-24.

----------

ResearchBlogging.org Bashir, S., & AL-Ayadhi, L. (2014). Alterations in plasma dipeptidyl peptidase IV in autism: A pilot study Neurology, Psychiatry and Brain Research, 20 (2), 41-44 DOI: 10.1016/j.npbr.2014.03.001